financetom
Business
financetom
/
Business
/
Form 8.3 - American Axle & Manufacturing Holdings, Inc.
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Form 8.3 - American Axle & Manufacturing Holdings, Inc.
Oct 21, 2025 7:42 AM

LONDON--(BUSINESS WIRE)--

 

FORM 8.3

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY

A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

Rule 8.3 of the Takeover Code (the “Code”)

1. KEY INFORMATION

(a) Full name of discloser:

 

Millennium International Management LP

(b) Owner or controller of interests and short positions disclosed, if different from 1(a):

The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.

 

 

(c) Name of offeror/offeree in relation to whose relevant securities this form relates:

Use a separate form for each offeror/offeree

 

American Axle & Manufacturing Holdings, Inc.

(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:

 

 

(e) Date position held/dealing undertaken:

For an opening position disclosure, state the latest practicable date prior to the disclosure

 

20th October 2025

(f) In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?

If it is a cash offer or possible cash offer, state “N/A”

 

Yes, Dowlais Group plc

2. POSITIONS OF THE PERSON MAKING THE DISCLOSURE

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)

Class of relevant security:

 

USD 0.01 common (US0240611030)

 

 

 

Interests

 

Short positions

 

Number

 

%

 

Number

 

%

(1) Relevant securities owned and/or controlled:

 

1,428,163

 

1.204%

 

93,263

 

0.079%

(2) Cash-settled derivatives:

 

 

-

 

-

 

4,072,427

 

3.432%

(3) Stock-settled derivatives (including options) and agreements to purchase/sell:

 

-

 

-

 

-

 

-

TOTAL:

 

1,428,163

 

1.204%

 

4,165,690

 

3.510%

All interests and all short positions should be disclosed.

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

(b) Rights to subscribe for new securities (including directors’ and other employee options)

Class of relevant security in relation to which subscription right exists:

 

 

Details, including nature of the rights concerned and relevant percentages:

 

 

3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

The currency of all prices and other monetary amounts should be stated.

(a) Purchases and sales

Class of relevant security

Purchase/sale

 

Number of securities

Price per unit (USD)

US0240611030

Purchase

20

5.70

US0240611030

Sale

5,470

5.70

US0240611030

Sale

200

5.71

US0240611030

Sale

4,908

5.68

US0240611030

Sale

443

5.64

US0240611030

Purchase

541

5.69

US0240611030

Sale

4,651

5.69

US0240611030

Purchase

594

5.67

US0240611030

Sale

5,935

5.67

US0240611030

Sale

13,176

5.66

US0240611030

Purchase

1

5.65

US0240611030

Sale

9,746

5.65

US0240611030

Sale

1,000

5.61

US0240611030

Sale

1,000

5.62

US0240611030

Purchase

774

5.70

US0240611030

Purchase

2,666

5.71

US0240611030

Purchase

5,230

5.68

US0240611030

Purchase

200

5.58

US0240611030

Purchase

200

5.64

US0240611030

Purchase

4,797

5.69

US0240611030

Purchase

5,794

5.67

US0240611030

Sale

3,326

5.67

US0240611030

Purchase

1,556

5.66

US0240611030

Purchase

300

5.65

US0240611030

Purchase

100

5.62

US0240611030

Purchase

300

5.59

US0240611030

Purchase

100

5.63

US0240611030

Purchase

200

5.72

US0240611030

Sale

4,068

5.70

US0240611030

Sale

557

5.71

US0240611030

Purchase

563

5.68

US0240611030

Sale

48,352

5.68

US0240611030

Purchase

791

5.69

US0240611030

Sale

68,040

5.69

US0240611030

Purchase

710

5.67

US0240611030

Sale

19,351

5.67

US0240611030

Purchase

316

5.66

US0240611030

Sale

28,503

5.66

US0240611030

Purchase

344

5.65

US0240611030

Sale

3,947

5.65

US0240611030

Purchase

1,557

5.62

US0240611030

Purchase

743

5.63

US0240611030

Purchase

100

5.73

US0240611030

Purchase

235

5.74

US0240611030

Purchase

465

5.72

US0240611030

Sale

2,913

5.72

US0240611030

Purchase

566

5.60

US0240611030

Purchase

20

5.75

US0240611030

Sale

1

5.57

US0240611030

Purchase

714

5.70

US0240611030

Sale

48

5.70

US0240611030

Purchase

512

5.71

US0240611030

Sale

319

5.71

US0240611030

Purchase

4,737

5.68

US0240611030

Sale

3,130

5.68

US0240611030

Sale

100

5.58

US0240611030

Purchase

85

5.64

US0240611030

Purchase

1,993

5.69

US0240611030

Purchase

2,577

5.67

US0240611030

Sale

5,270

5.67

US0240611030

Purchase

1,886

5.66

US0240611030

Sale

1,413

5.66

US0240611030

Purchase

56

5.65

US0240611030

Sale

20

5.65

US0240611030

Purchase

84

5.63

US0240611030

Purchase

200

5.72

US0240611030

Sale

21

5.70

US0240611030

Purchase

200

5.71

US0240611030

Sale

2,010

5.71

US0240611030

Purchase

14

5.68

US0240611030

Sale

7,966

5.68

US0240611030

Purchase

72

5.64

US0240611030

Purchase

68

5.69

US0240611030

Sale

1,494

5.69

US0240611030

Purchase

6,910

5.67

US0240611030

Sale

6,893

5.67

US0240611030

Purchase

304

5.66

US0240611030

Sale

1,317

5.66

US0240611030

Purchase

3,636

5.65

US0240611030

Sale

961

5.65

US0240611030

Purchase

100

5.59

US0240611030

Purchase

43

5.73

US0240611030

Purchase

100

5.74

US0240611030

Purchase

215

5.60

US0240611030

Purchase

45

5.69

US0240611030

Sale

234

5.66

(b) Cash-settled derivative transactions

Class of relevant security

 

Product description

e.g. CFD

 

Nature of dealing

e.g. opening/closing a long/short position, increasing/reducing a long/short position

 

Number of reference securities

 

Price per unit

 

US0240611030

 

Equity Swap

 

Increasing a Short Position

 

42,500

 

4.21 GBP

US0240611030

 

Equity Swap

 

Increasing a Short Position

 

21,250

 

4.24 GBP

(c) Stock-settled derivative transactions (including options)

(i) Writing, selling, purchasing or varying

Class of relevant security

 

Product description e.g. call option

 

Writing, purchasing, selling, varying etc.

 

Number of securities to which option relates

 

Exercise price per unit

 

Type

e.g. American, European etc.

 

Expiry date

 

Option money paid/ received per unit

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(ii) Exercise

Class of relevant security

 

Product description

e.g. call option

 

Exercising/ exercised against

 

Number of securities

 

Exercise price per unit

 

 

 

 

 

 

 

 

 

(d) Other dealings (including subscribing for new securities)

Class of relevant security

 

Nature of dealing

e.g. subscription, conversion

 

Details

 

Price per unit (if applicable)

 

 

 

 

 

 

 

 

4. OTHER INFORMATION

(a) Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer:

Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state “none”

 

NONE

 

(b) Agreements, arrangements or understandings relating to options or derivatives

Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state “none”

 

NONE

 

(c) Attachments

Class of relevant security:

 

USD 0.01 common (US0240611030)

 

 

 

Interests

 

Short positions

 

Number

 

%

 

Number

 

%

(1) Relevant securities owned and/or controlled:

 

1,428,163

 

1.204%

 

93,263

 

0.079%

(2) Cash-settled derivatives:

 

 

-

 

-

 

4,072,427

 

3.432%

(3) Stock-settled derivatives (including options) and agreements to purchase/sell:

 

-

 

-

 

-

 

-

TOTAL:

 

1,428,163

 

1.204%

 

4,165,690

 

3.510%

0

Class of relevant security:

 

USD 0.01 common (US0240611030)

 

 

 

Interests

 

Short positions

 

Number

 

%

 

Number

 

%

(1) Relevant securities owned and/or controlled:

 

1,428,163

 

1.204%

 

93,263

 

0.079%

(2) Cash-settled derivatives:

 

 

-

 

-

 

4,072,427

 

3.432%

(3) Stock-settled derivatives (including options) and agreements to purchase/sell:

 

-

 

-

 

-

 

-

TOTAL:

 

1,428,163

 

1.204%

 

4,165,690

 

3.510%

1

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at [email protected]. The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s disclosure requirements on +44 (0)20 7638 0129.

The Code can be viewed on the Panel’s website at www.thetakeoverpanel.org.uk.

Source: Millennium Partners, L.P.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
First United Q2 net income rises on higher loan yields
First United Q2 net income rises on higher loan yields
Jul 21, 2025
Overview * First United Q2 net income rises to $6.0 mln, driven by increased loan yields * Net interest margin improves to 3.65%, partly helped by stable funding costs * The bank holding company's Q2 pre-tax profit rises to $7.96 mln from $6.52 mln year ago Outlook * First United expects stronger growth in second half of 2025 due to...
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Google agrees $36 million fine for anti-competitive deals with Australia telcos
Aug 17, 2025
SYDNEY, Aug 18 (Reuters) - Google agreed on Monday to pay a A$55 million ($35.8 million) fine in Australia after the consumer watchdog found it had hurt competition by paying the country's two largest telcos to pre-install its search application on Android phones, excluding rival search engines. The fine extends a bumpy period for the Alphabet-owned internet giant in Australia,...
MGP Ingredients Names Julie Francis as President, CEO
MGP Ingredients Names Julie Francis as President, CEO
Jul 21, 2025
08:27 AM EDT, 07/21/2025 (MT Newswires) -- MGP Ingredients ( MGPI ) said Monday its board appointed Julie Francis as the company's president and chief executive officer, effective immediately. Francis takes over from Interim President and CEO Brandon Gall, who served in the role since January 1 and will continue as the company's chief financial officer, according to a statement....
Johnson & Johnson Files FDA Application for Oral Psoriasis Drug Candidate Icotrokinra
Johnson & Johnson Files FDA Application for Oral Psoriasis Drug Candidate Icotrokinra
Jul 21, 2025
08:27 AM EDT, 07/21/2025 (MT Newswires) -- Johnson & Johnson ( JNJ ) said Monday it has submitted a new drug application to the US Food and Drug Administration seeking the first approval of icotrokinra, which is intended for the treatment of adults and pediatric patients aged 12 years and older with moderate to severe plaque psoriasis. The application included...
Copyright 2023-2026 - www.financetom.com All Rights Reserved